Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012739 (disseminated intravascular coagulation)
 8,673 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A rapid technique suitable for routine laboratory use for determining the percentage of large platelets in the peripheral blood is described. In 50 haematologically normal subjects, megathrombocytes (platelets with a volume of 16-33 fl) constituted 3.0-16.6% (mean +/- 2 SD) of the platelet count. Of the 10 patients examined with immune thrombocytopenic purpura, an increased percentage of megathrombocytes (mean 26.6%) was found in all with severe thrombocytopenia, and in 6 of 8 (mean 19.8%) with moderate thrombocytopenia; the percentages were not influenced by prior splenectomy. Six of 12 patients with severe hypomegakaryocytic thrombocytopenia had an increased percentage of large platelets (mean 15.9%), as did one of 21 patients (mean 9.9%) with moderate thrombocytopenia of simimlar aetiology. When patients with nearly identical platelet counts were compared, the mean percentage of megathrombocytes was greater in immune than in hypomegakaryocytic thrombocytopenia for both severe (t=3.17, P less than 0.01) and moderate (t=4.5, P less than 0.001) thrombocytopenia. An increased percentage of large platelets (mean 21.9%) was found in 6 to 8 patients with disseminated intravascular coagulation, in 7 of 20 (mean 15.8%) with chronic myeloproliferative disorders and in one of 15 (mean 8.8%) with reactive thrombocytosis. Determination of the percentage of megathrombocytes by this technique assists in differentiating immune thrombocytopenia from hypomegakaryocytic thrombocytopenia, in diagnosing mild disseminated intravascular coagulation, and in determining whether thrombocytosis is reactive or a consequence of a myeloproliferative disorders.
 ...
PMID:A rapid method for assessing megathrombocytes: its application to thrombocytotic and acquired thrombocytopenic states. 98 70

Thirty-six patients with chronic myeloproliferative disorders (CMPD) were studied as regards blood coagulation and fibrinolysis. These studies revealed various mild abnormalities: activated thromboplastin time (APTT) tended to prolong and the level of factor V decreased significantly. In several cases, the levels of D-dimer, thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex were elevated compared to normal. These results suggest that abnormal coagulation system in the patients with CMPD is related to low grade disseminated intravascular coagulation. Many coagulation factors did not correlate with peripheral blood cell counts. Two patients with polycythemia vera were evaluated for several abnormalities of the coagulation system before and during treatment. Coagulation abnormalities persisted after hematologic control had been achieved. Our results suggest that patients with CMPD have a chronic state of abnormal blood coagulation system even after normalization of blood cell counts.
 ...
PMID:[Abnormal blood coagulation and fibrinolysis in chronic myeloproliferative disorders]. 187 Feb 70

Patients with chronic myeloproliferative disorders (CMPD) frequently have abnormalities of plasma von Willebrand factor (vWf) multimers. The pathogenesis of this phenomenon is still unknown. In order to evaluate the possibility of ex vivo degradation of vWf during blood processing, we compared vWf antigen, ristocetin cofactor and the multimeric composition of vWf in plasmas obtained in the presence of trisodium citrate with or without calcium-dependent protease inhibitors (leupeptin, N-ethylmaleimide and Na2EDTA). The subjects included 20 patients with CMPD, 11 with other diseases and 8 normal subjects. In patients with CMPD and normal subjects, the values of vWf antigen, ristocetin cofactor, ristocetin cofactor/vWf antigen ratio and the relative amount of large multimers of vWf did not significantly differ from each other in plasma samples with and without protease inhibitors. In other diseases, especially in a patient with disseminated intravascular coagulation, a somewhat higher amount of large multimers were found in plasma with protease inhibitors than without inhibitors. These findings indicate that the ex vivo proteolysis during blood processing is negligible in patients with CMPD, and that the observed abnormalities in vWf is an in vivo phenomenon.
 ...
PMID:Plasma von Willebrand factor proteolysis in patients with chronic myeloproliferative disorders: no possibility of ex vivo degradation by calcium-dependent proteases. 269 24